chondroitin-sulfates and Cat-Diseases

The purpose of this study was to evaluate the pain-alleviating and activity-enhancing effects of glucosamine/chondroitin sulfate (Dasuquin) in cats that had degenerative joint disease (DJD) and owner-noted mobility/activity impairment. We hypothesized that the nutritional supplement would produce pain-relieving and activity-enhancing effects in cats with painful DJD.. In this prospective, randomized, stratified, double-blind, placebo-controlled clinical trial, 59 cats with DJD pain were assigned to receive a placebo (n = 30) or supplement (n = 29) for 6 weeks after 2 weeks of placebo. Outcome measures (at-home accelerometry and client-specific outcome measures [feline (CSOMf); Feline Musculoskeletal Pain Index (FMPI); quality of life (QoL)]; and veterinarian examination) were collected at days 14, 28, 42 and 56.. This study showed a strong placebo effect. The glucosamine/chondroitin sulfate supplement did not show pain-relieving effects when compared with placebo.

Topics: Animals; Cat Diseases; Cats; Chondroitin Sulfates; Double-Blind Method; Glucosamine; Joint Diseases; Musculoskeletal Pain; Prospective Studies; Quality of Life; Treatment Outcome

Topics: Animal Feed; Animals; Cat Diseases; Cats; China; Chondroitin Sulfates; Dog Diseases; Dogs; Drug Contamination; Food Contamination; France; Fraud; Heparin; Humans; Infant; Milk; Milk Proteins; Poisoning; Public Health; Rats; Triazines